Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0028 | 0.5 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0028 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0028 | 0.5 | 0.5 |
Plasmodium vivax | RNA helicase-1, putative | 0.0028 | 0.5 | 0.5 |
Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0028 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0028 | 0.5 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0028 | 0.5 | 0.5 |
Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.0028 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0028 | 0.5 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0028 | 0.5 | 0.5 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0028 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0028 | 0.5 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0028 | 0.5 | 0.5 |
Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0028 | 0.5 | 0.5 |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0028 | 0.5 | 0.5 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0028 | 0.5 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0028 | 0.5 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0028 | 0.5 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0028 | 0.5 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0028 | 0.5 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0028 | 0.5 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0028 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 1.5 uM | Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 1.5 uM | Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 2.9 uM | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 2.9 uM | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 3.2 uM | Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 3.2 uM | Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 4.6 uM | Antiproliferative activity against human CEM cells | ChEMBL. | 17092728 |
IC50 (functional) | = 4.6 uM | Antiproliferative activity against human Hep2 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 4.6 uM | Antiproliferative activity against human CEM cells | ChEMBL. | 17092728 |
IC50 (functional) | = 4.6 uM | Antiproliferative activity against human Hep2 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 5 uM | Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 5 uM | Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 6.8 uM | Antiproliferative activity against mouse L1210 cells | ChEMBL. | 17092728 |
IC50 (functional) | = 6.8 uM | Antiproliferative activity against mouse L1210 cells | ChEMBL. | 17092728 |
IC50 (functional) | = 7.2 uM | Antiproliferative activity against human Molt4/C8 cells | ChEMBL. | 17092728 |
IC50 (functional) | = 8.7 uM | Antiproliferative activity against human MiaPaCa2 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
IC50 (functional) | = 8.7 uM | Antiproliferative activity against human MiaPaCa2 cells after 72 hrs by MTT assay | ChEMBL. | 17092728 |
MCC (ADMET) | >= 18 uM | Cytotoxicity against HEL cells | ChEMBL. | 17092728 |
MCC (ADMET) | >= 18 uM | Cytotoxicity against HEL cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against HSV1 KOS-induced cytopathogenicity in HEL cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against HSV2 G-induced cytopathogenicity in HEL cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against Vaccinia virus-induced cytopathogenicity in HEL cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in HEL cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against HSV1 TK- KOS ACV -induced cytopathogenicity in HEL cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against Sindbis virus-induced cytopathogenicity in Vero cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against Coxsackie virus B4-induced cytopathogenicity in Vero cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against Punta Toro virus-induced cytopathogenicity in Vero cells | ChEMBL. | 17092728 |
MIC (functional) | > 18 uM | Antiviral activity against in Vesicular stomatitis virus- induced cytopathogenicity in HeLa cells | ChEMBL. | 17092728 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Mus musculus | ChEMBL23 | 17092728 | |
Homo sapiens | ChEMBL23 | 17092728 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.